Clinical Trial

Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety and efficacy of Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, in combination with stereotactic body radiotherapy (SBRT) and chemotherapy for treating locally advanced pancreatic cancer (LAPC). The Phase Ib portion is a dose-escalation study to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and the recommended Phase II dose (RP2D) of Ivonescimab. The Phase II portion will assess the median progression-free survival (mPFS) of patients receiving Ivonescimab with SBRT (25-50Gy/5F) and modified FOLFIRINOX chemotherapy. The study aims to provide critical insights into treatment options for LAPC and inform future therapeutic strategies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-19.
Trial Details
NCT Number NCT06844422
Lead Sponsor Shandong Cancer Hospital and Institute
Conditions Pancreatic Cancer
Enrollment 37 participants
Start Date 2025-02-08
Primary Completion 2028-02-18 (estimated)
Study Completion 2028-02-18 (estimated)
Updated on ClinicalTrials.gov 2026-04-28